EUVIMEDEUVIMED entdecken
Open Access

Targeting HSP70‐E7 Interaction With SHetA2: A Novel Therapeutic Strategy for Cervical Cancer

Justin Garland iD, Showket Hussain iD, Rajani Rai iD, Amy L Kennedy iD, Zitha Redempta Isingizwe iD, Doris M Benbrook iD

Journal of Medical Virology · 2024

DOI: 10.1002/jmv.70088 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medical Virology, 2024. Verfasst von Justin Garland und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA. Hauptthemen laut MEDLINE: HSP70 Heat-Shock Proteins, Uterine Cervical Neoplasms, Papillomavirus E7 Proteins, Oncogene Proteins, Viral. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, This research was funded by National Cancer Institute., National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cervical cancer is predominantly driven by persistent infections with high‐risk human papillomavirus and the continuous activity of its E6 and E7 oncoproteins. This study explored the role of heat shock proteins 70 kDa (HSP70s) in enhancing the function of these oncoproteins and examined the impact of SHetA2, an investigational new drug, on this interaction. We found that HSP70 specifically binds to E7, but not E6, protein and that SHetA2 disrupts this binding. This disruption led to a significant reduction in E6 and E7 mRNA and E7 protein levels, while effects on E6 protein levels were minimal. SHetA2 treatment also resulted in altered levels of cell cycle regulatory proteins, reduced cell cycle progression, and decreased metabolic viability in cervical cancer cell lines and xenograft models. These findings support the potential of SHetA2 to impair cervical cancer progression by targeting HSP70/E7 interactions, highlighting its promise as a therapeutic strategy for treating cervical cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HSP70 Heat-Shock ProteinsUterine Cervical NeoplasmsPapillomavirus E7 ProteinsOncogene Proteins, ViralHumansFemaleAnimalsCell Line, TumorMiceProtein BindingRepressor ProteinsCell Cycle

Stichwörter der Autor:innen

E7HPVHSP70SHetA2cervical cancerheat shock protein 70human papillomavirusinvestigational new drugproteasomal degradation

Substanzen

HSP70 Heat-Shock ProteinsPapillomavirus E7 ProteinsOncogene Proteins, ViralRepressor Proteins

Autor:innen und Institutionen

  • Department of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA.
  • Division of Molecular Diagnostics and Molecular Oncology, ICMR-National Institute of Cancer Prevention and Research, Noida, India.
  • Gynecologic Oncology Section, Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA.

ORCID-Profile: Justin Garland, Showket Hussain, Rajani Rai, Amy L Kennedy, Zitha Redempta Isingizwe, Doris M Benbrook

Förderung

  • NCI NIH HHS
  • This research was funded by National Cancer Institute.
  • National Cancer Institute

Zitieren

APA

Garland, J., Hussain, S., Rai, R., Kennedy, A. L., Isingizwe, Z. R., & Benbrook, D. M. (2024). Targeting HSP70‐E7 Interaction With SHetA2: A Novel Therapeutic Strategy for Cervical Cancer. Journal of Medical Virology. https://doi.org/10.1002/jmv.70088

Vancouver

Garland J, Hussain S, Rai R, Kennedy AL, Isingizwe ZR, Benbrook DM. Targeting HSP70‐E7 Interaction With SHetA2: A Novel Therapeutic Strategy for Cervical Cancer. Journal of Medical Virology. 2024. doi:10.1002/jmv.70088

BibTeX
@article{Garland2024,
  author = {Garland, Justin and Hussain, Showket and Rai, Rajani and Kennedy, Amy L and Isingizwe, Zitha Redempta and Benbrook, Doris M},
  title = {Targeting HSP70‐E7 Interaction With SHetA2: A Novel Therapeutic Strategy for Cervical Cancer},
  journal = {Journal of Medical Virology},
  year = {2024},
  doi = {10.1002/jmv.70088}
}
Kostenlos starten →